Psychosocial Mobile App for Chronic Graft-Versus-Host Disease

Description

The purpose of this research study is to see whether a psychosocial mobile app called Horizons is effective at improving quality of life, symptom burden, psychological distress, and coping in patients living with chronic graft-versus host disease (GVHD)

Conditions

Chronic Graft-Versus-Host Disease, Allogeneic Stem Cell Transplant

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this research study is to see whether a psychosocial mobile app called Horizons is effective at improving quality of life, symptom burden, psychological distress, and coping in patients living with chronic graft-versus host disease (GVHD)

Randomized Controlled Trial of a Psychosocial Mobile Application (App) to Promote Coping for Patients With Chronic Graft-Versus-Host Disease (GVHD)

Psychosocial Mobile App for Chronic Graft-Versus-Host Disease

Condition
Chronic Graft-Versus-Host Disease
Intervention / Treatment

-

Contacts and Locations

Boston

Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States, 02215

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Adult patients (≥18 years) who underwent allogeneic hematopoietic stem cell transplant (HCT).
  • * Have moderate to severe chronic GVHD based on their oncology clinician assessment as documented in the Electronic Health Record.
  • * Ability to comprehend and speak English as the HORIZONs app is only available in English.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Massachusetts General Hospital,

Areej El-Jawahri, MD, PRINCIPAL_INVESTIGATOR, Massachusetts General Hospital

Study Record Dates

2025-04-01